MA49514B1 - Particules virales recombinantes avec tropisme modifié, et leurs utilisations pour l'introduction ciblée de matériel génétique dans des cellules humaines - Google Patents
Particules virales recombinantes avec tropisme modifié, et leurs utilisations pour l'introduction ciblée de matériel génétique dans des cellules humainesInfo
- Publication number
- MA49514B1 MA49514B1 MA49514A MA49514A MA49514B1 MA 49514 B1 MA49514 B1 MA 49514B1 MA 49514 A MA49514 A MA 49514A MA 49514 A MA49514 A MA 49514A MA 49514 B1 MA49514 B1 MA 49514B1
- Authority
- MA
- Morocco
- Prior art keywords
- recombinant viral
- human cells
- genetic material
- viral particles
- targeted introduction
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 239000002245 particle Substances 0.000 title abstract 2
- 230000003612 virological effect Effects 0.000 title abstract 2
- 210000005260 human cell Anatomy 0.000 title 1
- 230000010415 tropism Effects 0.000 title 1
- 239000003446 ligand Substances 0.000 abstract 2
- 230000008685 targeting Effects 0.000 abstract 2
- 108090000565 Capsid Proteins Proteins 0.000 abstract 1
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 1
- 210000000234 capsid Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000002458 cell surface marker Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Abstract
L'invention concerne des compositions et des procédés pour rediriger des particules de capside virale recombinées par l'intermédiaire d'une paire de liaison de protéine:protéine spécifique qui forme une liaison covalente, par exemple isopeptidique, pour présenter un ligand de ciblage sur la protéine de capside, le ligand de ciblage se liant spécifiquement à un marqueur de surface cellulaire exprimé sur la cellule d'intérêt.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762525708P | 2017-06-27 | 2017-06-27 | |
PCT/US2018/039878 WO2019006046A2 (fr) | 2017-06-27 | 2018-06-27 | Particules virales recombinées à tropisme modifié et utilisations associées pour l'introduction ciblée de matériel génétique dans des cellules humaines |
Publications (2)
Publication Number | Publication Date |
---|---|
MA49514A MA49514A (fr) | 2020-05-06 |
MA49514B1 true MA49514B1 (fr) | 2023-06-28 |
Family
ID=63080488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA49514A MA49514B1 (fr) | 2017-06-27 | 2018-06-27 | Particules virales recombinantes avec tropisme modifié, et leurs utilisations pour l'introduction ciblée de matériel génétique dans des cellules humaines |
Country Status (28)
Country | Link |
---|---|
US (1) | US20200140492A1 (fr) |
EP (2) | EP3645553B1 (fr) |
JP (2) | JP2020525020A (fr) |
KR (1) | KR20200021987A (fr) |
CN (2) | CN110997699A (fr) |
AU (2) | AU2018290885B2 (fr) |
BR (1) | BR112019027866A2 (fr) |
CA (1) | CA3066950A1 (fr) |
CL (2) | CL2019003843A1 (fr) |
CO (1) | CO2019014684A2 (fr) |
CY (1) | CY1126149T1 (fr) |
DK (1) | DK3645553T3 (fr) |
ES (1) | ES2943020T3 (fr) |
FI (1) | FI3645553T3 (fr) |
HR (1) | HRP20230538T1 (fr) |
HU (1) | HUE061908T2 (fr) |
IL (1) | IL271570A (fr) |
LT (1) | LT3645553T (fr) |
MA (1) | MA49514B1 (fr) |
MD (1) | MD3645553T2 (fr) |
MX (2) | MX2020000246A (fr) |
PH (1) | PH12019550269A1 (fr) |
PL (1) | PL3645553T3 (fr) |
PT (1) | PT3645553T (fr) |
RS (1) | RS64233B1 (fr) |
SG (1) | SG11201911614XA (fr) |
SI (1) | SI3645553T1 (fr) |
WO (1) | WO2019006046A2 (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
US20200407751A1 (en) * | 2018-02-28 | 2020-12-31 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Modular system for gene and protein delivery based on aav |
US11453883B2 (en) | 2018-04-05 | 2022-09-27 | Bio-Rad Abd Serotec Gmbh | Display systems for proteins of interest |
JP2022525775A (ja) * | 2019-03-18 | 2022-05-19 | バイオ-ラッド エービーディー セロテック ゲーエムベーハー | SpyTag含有ペリプラズム融合タンパク質のプロテアーゼTSP及びOMPT分解からの保護 |
AR118997A1 (es) | 2019-05-24 | 2021-11-17 | Regeneron Pharma | Partículas virales modificadas y usos de estas |
EP3983117A4 (fr) * | 2019-06-11 | 2023-06-21 | Chevron U.S.A. Inc. | Membranes pour l'élimination de contaminants d'un gaz naturel et leurs procédés d'utilisation |
GB201915905D0 (en) * | 2019-11-01 | 2019-12-18 | Spybiotech Ltd | Viruses with modified capsid proteins |
US20230002451A1 (en) * | 2019-11-08 | 2023-01-05 | President And Fellows Of Harvard College | Viral capsid polypeptides |
CN114632148A (zh) * | 2020-12-15 | 2022-06-17 | 榕森生物科技(北京)有限公司 | 病原样抗原疫苗及其制备方法 |
CN114634578B (zh) * | 2020-12-15 | 2024-04-02 | 榕森生物科技(北京)有限公司 | 针对新型冠状病毒感染的疫苗组合物 |
CA3233698A1 (fr) | 2021-11-04 | 2023-05-11 | Regeneron Pharmaceuticals, Inc. | Particules virales reciblees sur le muscle squelettique |
CN114213505B (zh) * | 2021-12-10 | 2022-09-20 | 和元生物技术(上海)股份有限公司 | 一种适用于特异感染u87-mg细胞的腺相关病毒突变体 |
WO2023220603A1 (fr) | 2022-05-09 | 2023-11-16 | Regeneron Pharmaceuticals, Inc. | Vecteurs et procédés de production d'anticorps in vivo |
WO2023240124A1 (fr) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Particules virales pseudotypées pour le ciblage de cellules exprimant un tcr |
WO2024026494A1 (fr) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Particules virales reciblées vers le récepteur 1 de transferrine |
CN117723749A (zh) * | 2024-02-07 | 2024-03-19 | 南昌大学 | 基于分子粘合剂的动态光散射免疫传感检测方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1286981C (zh) * | 2004-11-30 | 2006-11-29 | 华中科技大学同济医学院附属同济医院 | 表达人类cyp2j2反义基因的重组腺相关病毒及其制备方法 |
US20100203083A1 (en) | 2007-05-31 | 2010-08-12 | Medigene Ag | Mutated structural protein of a parvovirus |
LT2954779T (lt) | 2009-12-10 | 2019-05-27 | Regeneron Pharmaceuticals, Inc. | Pelės, gaminančios sunkiosios grandinės antikūnus |
GB201002362D0 (en) | 2010-02-11 | 2010-03-31 | Isis Innovation | Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds |
AR094403A1 (es) * | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
JP6636498B2 (ja) | 2014-03-21 | 2020-01-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 単一ドメイン結合タンパク質を作る非ヒト動物 |
US20160018835A1 (en) * | 2014-07-18 | 2016-01-21 | Retroficiency, Inc. | System and method for virtual energy assessment of facilities |
US10526376B2 (en) * | 2015-01-15 | 2020-01-07 | University Of Copenhagen | Virus-like particle with efficient epitope display |
US20180298098A1 (en) | 2015-02-26 | 2018-10-18 | Var2 Pharmaceutical Aps | Immunotherapeutic targeting of placental-like chondroitin sulfate using chimeric antigen receptors (cars) and immunotherapeutic targeting of cancer using cars with split-protein binding systems |
EP3141600A1 (fr) | 2015-09-11 | 2017-03-15 | Institut National de la Recherche Agronomique | Polypeptides de fusion de la proteine d'enveloppe de nepovirus et leurs utilisations |
WO2018035503A1 (fr) | 2016-08-18 | 2018-02-22 | The Regents Of The University Of California | Ingénierie génomique de crispr-cas par l'intermédiaire d'un système d'administration d'aav modulaire |
US20200407751A1 (en) * | 2018-02-28 | 2020-12-31 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Modular system for gene and protein delivery based on aav |
-
2018
- 2018-06-27 CN CN201880054254.8A patent/CN110997699A/zh active Pending
- 2018-06-27 SI SI201830908T patent/SI3645553T1/sl unknown
- 2018-06-27 BR BR112019027866-4A patent/BR112019027866A2/pt unknown
- 2018-06-27 US US16/625,207 patent/US20200140492A1/en active Pending
- 2018-06-27 SG SG11201911614XA patent/SG11201911614XA/en unknown
- 2018-06-27 AU AU2018290885A patent/AU2018290885B2/en active Active
- 2018-06-27 ES ES18749636T patent/ES2943020T3/es active Active
- 2018-06-27 PL PL18749636.9T patent/PL3645553T3/pl unknown
- 2018-06-27 JP JP2019572025A patent/JP2020525020A/ja active Pending
- 2018-06-27 EP EP18749636.9A patent/EP3645553B1/fr active Active
- 2018-06-27 EP EP23153644.2A patent/EP4219529A1/fr active Pending
- 2018-06-27 LT LTEPPCT/US2018/039878T patent/LT3645553T/lt unknown
- 2018-06-27 WO PCT/US2018/039878 patent/WO2019006046A2/fr unknown
- 2018-06-27 MD MDE20200493T patent/MD3645553T2/ro unknown
- 2018-06-27 PT PT187496369T patent/PT3645553T/pt unknown
- 2018-06-27 MX MX2020000246A patent/MX2020000246A/es unknown
- 2018-06-27 KR KR1020207001284A patent/KR20200021987A/ko not_active Application Discontinuation
- 2018-06-27 CN CN202310837502.9A patent/CN116891534A/zh active Pending
- 2018-06-27 MA MA49514A patent/MA49514B1/fr unknown
- 2018-06-27 HR HRP20230538TT patent/HRP20230538T1/hr unknown
- 2018-06-27 FI FIEP18749636.9T patent/FI3645553T3/fi active
- 2018-06-27 HU HUE18749636A patent/HUE061908T2/hu unknown
- 2018-06-27 CA CA3066950A patent/CA3066950A1/fr active Pending
- 2018-06-27 DK DK18749636.9T patent/DK3645553T3/da active
- 2018-06-27 RS RS20230411A patent/RS64233B1/sr unknown
-
2019
- 2019-12-09 PH PH12019550269A patent/PH12019550269A1/en unknown
- 2019-12-19 IL IL271570A patent/IL271570A/en unknown
- 2019-12-24 CO CONC2019/0014684A patent/CO2019014684A2/es unknown
- 2019-12-26 CL CL2019003843A patent/CL2019003843A1/es unknown
-
2020
- 2020-01-08 MX MX2023009051A patent/MX2023009051A/es unknown
- 2020-12-30 CL CL2020003438A patent/CL2020003438A1/es unknown
-
2022
- 2022-10-27 JP JP2022172414A patent/JP2022186991A/ja active Pending
-
2023
- 2023-06-14 CY CY20231100276T patent/CY1126149T1/el unknown
- 2023-07-12 AU AU2023204611A patent/AU2023204611A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49514B1 (fr) | Particules virales recombinantes avec tropisme modifié, et leurs utilisations pour l'introduction ciblée de matériel génétique dans des cellules humaines | |
MA51353B1 (fr) | Sérotype du virus adéno-associé recombinant hybride entre aav9 et aavrh74 possédant un tropisme hépatique réduit | |
MA40309A1 (fr) | Anticorps anti-cd73 et leurs utilisations | |
MA37663A1 (fr) | Procédés et compositions permettant la modification de l'adn cible dirigée par l'arn et la modulation de la transcription dirigée par l'arn | |
MA42935B1 (fr) | Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations | |
MA39313A1 (fr) | Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers | |
MA46708B1 (fr) | Anticorps anti-pd1 et leurs utilisations | |
MA45029B1 (fr) | Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer | |
MY190209A (en) | A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same | |
MA42021A1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du poumon à petites cellules et d'autres cancers | |
ATE472334T1 (de) | Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind | |
MA44059A (fr) | Antigènes du virus de l'immunodéficience humaine, vecteurs, compositions, et leurs procédés d'utilisation | |
MA37619A1 (fr) | Anticorps anti-fcrn | |
WO2019009682A3 (fr) | Mutant crispr spécifique à une cible | |
MY162056A (en) | Diagnosis and treatment of cancer using anti -ereg antibody | |
MA37407B1 (fr) | Anticorps dirigés contre les ligands des récepteurs b1 de la bradykinine | |
MX2022001971A (es) | Polipeptidos de interleucina 2 (il-2) modificados, conjugados y usos de los mismos. | |
MA33921B1 (fr) | Polypeptide de fusion dirigé contre une tumeur induite par le virus eb et mutant de la colicine ia | |
MA40371B1 (fr) | Sélectivité efficace des protéines recombinées | |
FR3016888B1 (fr) | Synthetases de la colistine et cluster de genes correspondants | |
FR3061020B1 (fr) | Composition de fibrinogene humain | |
CL2022003101A1 (es) | Partículas virales recombinantes con tropismo modificado y sus usos (divisional de 201903843) | |
MA38501B1 (fr) | Anticorps humains de la protéine f du virus respiratoire syncytial et ses procédés d'utilisation | |
MA47657A1 (fr) | Compositions et méthodes pour l'internalisation d'enzymes | |
MX2016003302A (es) | Metodo de transfeccion de la version soluble pro-apoptotica de la proteina especifica del arresto celular 1 (tgas1) en celulas de glioma mediante nanoparticulas de poliplex-neurotensina. |